{"name":"Maravai LifeSciences","slug":"maravai","ticker":"MRVI","exchange":"NASDAQ","domain":"maravai.com","description":"Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in ","hq":"San Diego, CA","founded":0,"employees":"435","ceo":"Trey Martin","sector":"Life Sciences Tools / Nucleic Acids","stockPrice":3.15,"stockChange":0.26,"stockChangePercent":9,"marketCap":"$1.2B","metrics":{"revenue":260000000,"revenueGrowth":-11.8,"grossMargin":19.2,"rdSpend":17402000,"netIncome":-130773000,"cash":216890000,"dividendYield":0,"peRatio":-21.3,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Lumoxiti patent cliff ($100M at risk)","drug":"Lumoxiti","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Maravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Maravai LifeSciences reported fourth quarter and full year 2023 financial results, with revenue of $143.8 million and net income of $34.4 million.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Maravai LifeSciences Announces Collaboration with Biogen to Develop RNA-Based Therapies","summary":"Maravai LifeSciences announced a collaboration with Biogen to develop RNA-based therapies for neurological disorders.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"Maravai LifeSciences Receives FDA Clearance for New Oligonucleotide Synthesis Platform","summary":"Maravai LifeSciences received FDA clearance for its new oligonucleotide synthesis platform, which is designed to improve the efficiency and scalability of oligonucleotide production.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-02-27","type":"pipeline","source":"simplywall.st","summary":"Maravai LifeSciences Holdings (MRVI) Posts US$130.8m TTM Loss Challenging Margin Recovery Narratives - simplywall.st","headline":"Maravai LifeSciences Holdings (MRVI) Posts US$130.8m TTM Loss Challenging Margin Recovery Narratives","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-29","type":"pipeline","source":"simplywall.st","summary":"Maravai LifeSciences Holdings (NASDAQ:MRVI shareholders incur further losses as stock declines 11% this week, taking five-year losses to 90% - simplywall.st","headline":"Maravai LifeSciences Holdings (NASDAQ:MRVI shareholders incur further losses as stock declines 11% this week, taking fiv","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQeG9fSTNRVWVtcXJoVEVpRUJDdzY1VF9wSDQwUWk5VXl3aWN4NEVfQm80TnFuM0xqdnkzUnZJUVdpTG1Lb0M5SF93MlpqZ1dNTlBVbzM3cjVFZmVvcFRySGlwLUxmREtRaG9IU19YbmdhUi1qNkhyTXAzel9OMll2TjFyRUxaUVo1TVV1RGFORzRsMUhpZV9Da21TcWlNTXNkRGJKQWRlbXJXYWNnYmtlRA?oc=5","date":"2026-01-06","type":"pipeline","source":"Kalkine Media","summary":"Maravai LifeSciences (NASDAQ:MRVI) Nasdaq Index Life Sciences Inputs - Kalkine Media","headline":"Maravai LifeSciences (NASDAQ:MRVI) Nasdaq Index Life Sciences Inputs","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-05","type":"pipeline","source":"simplywall.st","summary":"Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 29% Jump Shows Its Popularity With Investors - simplywall.st","headline":"Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 29% Jump Shows Its Popularity With Investors","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-15","type":"pipeline","source":"simplywall.st","summary":"Is Maravai LifeSciences Holdings (NASDAQ:MRVI) Using Too Much Debt? - simplywall.st","headline":"Is Maravai LifeSciences Holdings (NASDAQ:MRVI) Using Too Much Debt?","sentiment":"neutral"},{"date":"2025-11-07","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-10-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-14","type":"earnings","source":"simplywall.st","summary":"Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Reported Earnings, And Analysts Cut Their Target Price - simplywall.st","headline":"Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Reported Earnings, And Analysts Cut Their Target Price","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPU2dGWUk0N2h3WTZmVmgzay1ReFZ5UmhzaGRtdkRRcnBlcnR1Ty1QSmJJUVR6d3NUeXhHUXJmdzdpQy14VFVEWTgzSzVjbFlRUndfRG5ZQnBXRFkyTGxUX2std0J4aU9zR2NWX0J5RHpQMHFNYmhWSnFjMFNrZEFEMVdxTm5uU3REamgzYkdGS290YzhCWnlibnJXX3ROWWwtamZiOHhEa2o3a1BkcGp4T3AxT19JVlF2UU1wNl9CdDJ4XzZ4N21r?oc=5","date":"2024-10-11","type":"deal","source":"GuruFocus","summary":"Maravai Lifesciences (MRVI) Stock Surges Over 5% Amid Strong Buy Recommendations - GuruFocus","headline":"Maravai Lifesciences (MRVI) Stock Surges Over 5% Amid Strong Buy Recommendations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE1Hc0x2MFF6MmVKZDN0a2dBN3hDTll4MzZrMUlOc0tWdlZKZXJmU0xfVUt2ZWlNSzVqX1BjVEpVM1JoX1lScU15aWVtUTFvLWxs?oc=5","date":"2024-03-26","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNM1RBaWZvVFlUWGtFU2kzMm5hY2pGVFhISEJIaGp0elI4cWpiVVY1aVJBQmFQWS14NE1tTGZwdWttbmNGZHh2eVhUX1NIWkNZUVFwYWh6S3ZfQVlLdTBkQm9sSV9HWU5pRXRFWnJKZnNISjVOcHJpTUhQbmhUZ0dUMnd3cGh2cFpsT3hkQXhhVGhleUE4S2tnWlhaeEFHV09mNXk4ODdoU1BfS3IycFFGZml0LVBTYlBPWUE4eWRsOVVNZFRBSHc4b3F5SmxXN3dIYml4UW5nU294cjdBaGM2dA?oc=5","date":"2022-02-25","type":"pipeline","source":"Reuters","summary":"EXCLUSIVE Sartorius in $11 bln bid for COVID vaccine reagent vendor Maravai -sources - Reuters","headline":"EXCLUSIVE Sartorius in $11 bln bid for COVID vaccine reagent vendor Maravai -sources","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE9rYllJMzZNZUxnSmJydHZlNkJfT2pYcmtKd0RWTTZsLXRpSnA0aXpxWnBDY2RmUTJFRW5FcklkRHpVUnpKa19qd1hjRE9DbWpyQmc?oc=5","date":"2021-02-23","type":"pipeline","source":"Yahoo Finance UK","summary":"Maravai LifeSciences Holdings, Inc. (MRVI) stock price, news, quote and history - Yahoo Finance UK","headline":"Maravai LifeSciences Holdings, Inc. (MRVI) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Lumoxiti","drugSlug":"moxetumomab-pasudotox","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Thermo Fisher Scientific","Agilent Technologies","Bio-Rad Laboratories"],"therapeuticFocus":["Oncology","Infectious Diseases"],"financials":{"source":"sec_edgar","revenue":185743000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":185743000,"period":"2025-12-31"},{"value":259185000,"period":"2024-12-31"},{"value":259185000,"period":"2024-12-31"},{"value":202627000,"period":"2024-09-30"},{"value":69025000,"period":"2024-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":17402000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-130773000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":770577000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":3.15,"previousClose":2.89,"fiftyTwoWeekHigh":4.11,"fiftyTwoWeekLow":1.67,"fiftyTwoWeekRange":"1.665 - 4.105","fiftyDayAverage":3.24,"twoHundredDayAverage":3.06,"beta":0.43,"enterpriseValue":731197312,"forwardPE":-21.3,"priceToBook":2.16,"priceToSales":6.24,"enterpriseToRevenue":3.94,"enterpriseToEbitda":-9.87,"pegRatio":0,"ebitda":-74121000,"ebitdaMargin":-39.9,"freeCashflow":-2768750,"operatingCashflow":-57573000,"totalDebt":364708000,"debtToEquity":97.9,"currentRatio":6.6,"returnOnAssets":-8.8,"returnOnEquity":-48.6,"analystRating":"","recommendationKey":"none","numberOfAnalysts":6,"targetMeanPrice":4.33,"targetHighPrice":5,"targetLowPrice":3,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":10.8,"institutionHeldPercent":90.7,"sharesOutstanding":146383162,"floatShares":98065008,"sharesShort":9722307,"shortRatio":7.15,"shortPercentOfFloat":6.6,"epsTrailing":-0.9,"epsForward":-0.15,"revenuePerShare":1.29,"bookValue":1.46,"officers":[{"age":63,"name":"Mr. Robert Andrew Eckert M.B.A.","title":"Chairman of the Board"},{"age":58,"name":"Mr. Bernd  Brust","title":"CEO & Director"},{"age":58,"name":"Mr. Rajesh J. Asarpota","title":"EVP & Chief Financial Officer"},{"age":null,"name":"Ms. Chanfeng  Zhao","title":"Senior VP & Chief Scientific Officer"},{"age":null,"name":"Ms. Debra  Hart","title":"Senior Director of Investor Relations"},{"age":44,"name":"Mr. Kurt A. Oreshack J.D.","title":"Executive VP, General Counsel & Secretary"},{"age":null,"name":"Ms. Judith A. Solecki","title":"Chief Human Resources Officer"},{"age":57,"name":"Ms. Christine  Dolan","title":"Executive VP & GM of Cygnus Technologies"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.maravai.com","phone":"858 546 0004"}}